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http://www.biomedcentral.com/1471-2407/12/425RESEARCH ARTICLE Open AccessA new score predicting the survival of patients
with spinal cord compression from myeloma
Sarah Douglas1, Steven E Schild2 and Dirk Rades1*Abstract
Background: This study was performed to create and validate a scoring system for the survival of patients with
malignant spinal cord compression (SCC) from myeloma.
Methods: Of the entire cohort (N = 216), 108 patients were assigned to a test group and 108 patients to a
validation group. In the test group, nine pre-treatment factors including age, gender, Eastern Cooperative Oncology
Group performance status (ECOG-PS), number of involved vertebrae, ambulatory status prior to radiotherapy, other
bone lesions, extraosseous lesions, interval from first diagnosis of myeloma to radiotherapy of SCC, and the time
developing motor deficits were retrospectively analyzed.
Results: On univariate analysis, improved survival was associated with ECOG-PS 1–2 (p = 0.006), being ambulatory
(p = 0.005), and absence of other bone lesions (p = 0.019). On multivariate analysis, ECOG-PS (p = 0.036) and
ambulatory status (p = 0.037) were significant; other bone lesions showed a strong trend (p = 0.06). These factors
were included in the score. The score for each factor was determined by dividing the 12-month survival rate (in%)
by 10. The total risk score was the sum of the three factor scores and ranged from 19 to 24 points. Three
prognostic groups were designed with the following 12-month survival rates: 49% for 19–20 points, 74% for 21–23
points, and 93% for 24 points (p = 0.002). In the validation group, the 12-month survival rates were 51%, 80%, and
90%, respectively (p < 0.001).
Conclusions: This score appears reproducible, because the 12-month survival rates of both the test and the
validation group were very similar. This new survival score can help personalize the treatment of patients with SCC
from myeloma and can be of benefit when counseling patients.
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Myeloma is one of the most common malignant diseases
leading to malignant spinal cord compression (SCC)
[1,2]. In contrast to patients with SCC from a solid
tumor, myeloma patients with SCC are usually not can-
didates for spinal surgery, because myeloma is an extra-
ordinarily radiosensitive lesion [2]. Thus, patients with
SCC from myeloma were exluded from the randomized
trial of Patchell et al. that compared radiotherapy alone
to radiotherapy plus upfront decompressive surgery in
patients with SCC [3]. Therefore, radiotherapy alone is
generally considered the standard treatment for SCC
from myeloma [2]. Personalizing cancer care is one of* Correspondence: rades.dirk@gmx.net
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reproduction in any medium, provided the orthe most important trends in oncology. In order to ad-
minister the best treatment regimen to the individual pa-
tient, it is mandatory to consider the patient’s survival
prognosis. Long term local control of SCC is dose
dependent. As such, patients with a more favorable
prognosis can benefit from longer-course radiotherapy
(mostly 30 Gy in 10 fractions over 2 weeks) in terms of
better local control, whereas patients with an unfavor-
able prognosis may only need to receive short-course
radiotherapy with an overall treatment time of one week
or less [4]. On the other hand, patients with an extraor-
dinarily good survival prognosis appear to benefit from
an escalation of the radiation dose beyond 30 Gy in 10
fractions [5]. These patients live long enough that local
failure can be an issue. Therefore, it is important to be
able to estimate the patient’s survival prognosis. Thisl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cause different primary tumors have different biological
behavior, it is important to have a specific survival score
for each tumor entity associated with SCC [1,2]. Patients
with SCC from myeloma must be considered unique, as
they have the best survival prognosis of all patients
developing SCC from a malignant disease [6]. In the
study presented here, we create and validate a survival
score for this group of patients.
Results
In the test group, survival was associated with the
Eastern Cooperative Oncology Group performance sta-
tus (ECOG-PS) (p = 0.006), ambulatory status prior toTable 1 Test group: Univariate analysis of pre-treatment facto
Survival at 6 mon
(%)
Age
≤ 63 years 82







Number of involved vertebrae
1-2 83
≥ 3 87
Ambulatory status prior to radiotherapy
Not Ambulatory 70







Interval from cancer diagnosis to radiotherapy of
MSCC
≤ 15 months 90
> 15 months 80
Time developing motor deficits
1-14 days 80
> 14 days 89
Radiation regimen
Short-course radiotherapy 81
Longer-course radiotherapy 87radiotherapy (p = 0.005), and other bone lesions (p = 0.019)
on univariate analysis (Table 1). In the corresponding
multivariate analysis, ECOG-PS (p = 0.036) and ambulatory
status prior to radiotherapy (p = 0.037) maintained signifi-
cance (Table 2). The presence of other bone lesions showed
a strong trend (p = 0.06). All three prognostic factors were
included in the scoring system. The scores for each of these
factors obtained from the 12-month survival rate are shown
in Table 3.
The addition of the three scores for each factor
resulted in total scores from 19 to 24 points (Figure 1).
According to the total scores, the patients of the test
group were divided into three prognostic groups, 19–20
points (group A, n = 26), 21–23 points (group B, n = 49),rs and the radiation regimen for survival

























Table 2 Test group: Multivariate analysis of pre-treatment factors and the radiation regimen for survival
Risk ratio 95%-confidence interval p-value
ECOG Performance status 2.09 1.05 – 4.12 0.036
Ambulatory status prior to radiotherapy 2.14 1.05 – 4.24 0.037
Other bone lesions 1.97 0.96 – 4.37 0.06
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survival rates were 49% for group A, 74% for group B, and
93% for group C (p = 0.002, Figure 2). The 12-month sur-
vival rates of the three prognostic groups A, B and C in
the validation group were 51%, 80%, and 90%, respectively
(p < 0.001, Figure 2). Thus, the corresponding survival
rates of the test group and the validation group were very
similar.
Discussion
Personalization of cancer treatment has been increas-
ingly emphasized in the literature. This is especially ob-
vious when one reviews the new targeted agents that
affect specific biochemical reactions and often have ac-
tivity specific to certain mutations of a biologically active
target molecule. Such an individualized approach should
take into account the patient’s survival time, particularly
in a palliative situation such as malignant SCC. There-
fore, survival scores that help the physician to tailor the
treatment to the individual patients are important. Since
the various tumors behave differently, it would be help-
ful to have a particular survival score for each tumor en-
tity, at least for the most common diseases associated
with SCC such as breast cancer, prostate cancer, non-
small cell lung cancer, and myeloma [1,2]. In the present
study, a survival score was designed particularly for
patients with SCC from myeloma. The score included
three prognostic factors, ECOG-PS, ambulatory status
prior to radiotherapy, and other bone lesions. These fac-
tors found to be significantly associated with survival
were also reported in our previous report on prognostic
factors for SCC from myeloma [7]. In contrast to the










Yesdetermined that extraosseous lesions were also signifi-
cantly associated with survival. However, we decided to
include only those prognostic factors found to be inde-
pendent in the multivariate analysis of the test group in
the present scoring system, because we felt that this
would make the score more robust. This approach was
supported by the fact that the 12-month survival rates of
the validation group were similar to those of the test
group.
Patients with SCC from myeloma have a better sur-
vival prognosis than patients with SCC from a solid
tumor [1,2]. This is reflected by the fact that the worst
prognostic group, group A, was the smallest group in
this study. Patients of group C had a very good progno-
sis with 12-month survival rates of 93% in the test group
and 90% in the validation group. According to a retro-
spective study, these patients appear to benefit from an
escalation of the radiation dose beyond the world wide
commonest regimen 30 Gy in 10 fractions in terms of
better treatment outcomes [5]. This may also apply to
patients of group B, whose 12-months survival rates
were 74% and 80%, respectively. In contrast, group A
patients who had the worst prognosis of the three
groups, may be candidates for 30 Gy in 10 fractions or
even a short-course regimen such as 20 Gy in 5 frac-
tions. These suggestions should be interpreted with cau-
tion, because the data included in this survival score
were retrospective in nature. Retrospective data always
bear the risk of including hidden selection biases. How-
ever, it would be difficult and take many years to per-
form a prospective trial with an adequate number of
patients with SCC from myeloma. The authors know of
no plans to perform just such a prospective trial.ng scores
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Figure 1 Test group: The total scores in relation to the 12-month survival rate (in%).
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This new survival score for patients with SCC from mye-
loma included three prognostic factors, ECOG-PS, ambu-
latory status prior to radiotherapy, and other bone lesions.
Three prognostic groups were identified based on risk
scores ranging from 19 to 24 points. The 12-month sur-
vival rates of each of the three prognostic groups in the
validation group were similar to those of the test group.











0 10 20 30 40 50 60 70 80 90 100 110
















0 10 20 30 40 50 60 70 80 90 100





Figure 2 Kaplan-Meier curves for survival of the three score
groups A (19–20 points), B (21–23 points), and C (24 points)
from the test group (top) and from the validation group
(bottom).information can contribute to personalization of the treat-
ment for SCC from myeloma. Furthermore, the score can
be helpful when counseling patients and relatives regard-
ing prognosis and therapy.
Methods
In this study, the data of 216 unselected patients being
irradiated for SCC from myeloma between 1992 and
2011 were retrospectively analyzed. Because this study
did not report on a clinical trial, and because the data
were retrospective in nature and analyzed anonymously,
approval by an ethic committee and informed consent
from the patienst were not necessary. Patients included
in this study received radiotherapy alone for SCC-related
motor deficits of the lower extremities, did not have
prior surgery or radiotherapy to the currently involved
parts of the spinal cord, did have adequate diagnostic
imaging with spinal CT or MRI was requested, and had
received corticosteroid treatment during radiotherapy.
Since the vast majority of the patients were already
known as myeloma patients, a biopsy of the spinal
lesions was not performed in most patients included in
this study. The data were collected from the patients
themselves, from their treating physicians, and from
their files. Radiotherapy was performed with 6–10 MeV
photon beams from a linear accelerator. The treatment
volumes generally encompassed one normal vertebra
above and below the involved parts of the spinal cord.
The 216 patients were alternately assigned to the test
group (N = 108, uneven numbers) or the validation
group (N = 108, even numbers). Patient characteristics of
these groups are given in Table 4. In the test group, nine
pre-treatment factors were investigated including age
(≤63 vs. ≥64 years; median age: 63 years), gender,
ECOG-PS (1–2 vs. 3–4), number of involved vertebrae
(1–2 vs. ≥3), pre-radiotherapy ambulatory status (not
ambulatory vs. ambulatory), other bone lesions prior to
radiotherapy (no vs. yes), extraosseous lesions prior to
radiotherapy (no vs. yes), interval between first diagnosis
of myeloma and radiotherapy of SCC (≤15 vs.
>15 months), and time of developing motor deficits
prior to radiotherapy (1–7 vs. >7 days). In the entire
Table 4 Patient characteristics of the test group and the validation group. The p-values were obtained from the
Chi-square test
Test group Validation group p-value
n patients (%) n patients (%)
Age
≤ 63 years 57 (53) 54 (50)
≥ 64 years 51 (47) 54 (50) 0.84
Gender
Female 38 (35) 42 (39)
Male 70 (65) 66 (71) 0.81
ECOG Performance status
1-2 75 (69) 70 (65)
3-4 33 (31) 38 (35) 0.73
Number of involved vertebrae
1-2 48 (44) 50 (46)
≥ 3 60 (56) 58 (54) 0.91
Ambulatory status prior to radiotherapy
Not Ambulatory 27 (25) 32 (30)
Ambulatory before RT 81 (75) 76 (70) 0.75
Other bone lesions
No 45 (42) 43 (40)
Yes 63 (58) 65 (60) 0.92
Extraosseous lesions
No 105 (97) 102 (94)
Yes 3 (3) 6 (6) 0.89
Interval from cancer diagnosis to radiotherapy of MSCC
≤ 15 months 58 (54) 59 (55)
> 15 months 50 (46) 49 (45) 0.95
Time developing motor deficits
1-14 days 46 (43) 50 (46)
> 14 days 62 (57) 58 (54) 0.78
Radiation regimen
Short-course radiotherapy 37 (34) 38 (35)
Longer-course radiotherapy 71 (66) 70 (65) 0.96
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who could walk without aid prior to radiotherapy and 80%
in those patients who could walk with aid (p = 0.92).
Because the 12-month survival rates were very similar,
these two groups were combined to the group
“ambulatory”.
In addition to the pre-treatment factors, the potential
impact of the radiation regimen (short-course radiother-
apy with 1x8 Gy or 5x4 Gy over 1 week vs. longer-course
radiotherapy with 10x3 Gy over 2 weeks, 14-15x2.5 Gy
over 3 weeks, or 20x2 Gy over 4 weeks) has been investi-
gated. Since other prognostic factors of multiple myeloma
such as beta-2 myoglobulin and serum creatinine werenot available in most patients being treated for SCC, an
oncologic emergency situation, these factors were not
included in the present study.
The univariate analysis was performed with the
Kaplan-Meier-method and the log-rank test [8]. The sig-
nificant prognostic factors (p < 0.05) were included in a
multivariate analysis performed with the Cox proportion
hazards model. The prognostic factors that were signifi-
cant in the multivariate analysis of the test group (p < 0.05)
or showed a strong trend (p ≤ 0.06) were included in the
survival score. The score for each significant prognostic
factor was determined by dividing the 12-month survival
rate (in%) by 10 according to our previous survival score
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total score represented the sum of the scores for each
factor.
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